Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker-driven phase 2 trial of nivolumab, nivolumab + ipilimumab, or VEGFR TKI in treatment-naive metastatic kidney cancer
2016-003099-28Phase 2Active
- Sponsor
- Arctic Therapeutics
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab, ipilimumab, sunitinib and pazopanib in renal cell carcinoma (RCC) and clear cell renal cell carcinoma (ccRCC) (3 arms), sponsored by Arctic Therapeutics. Primary endpoint: Objective response rate. Started Feb 2017; status: active.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2016-003099-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003099-28.